$LFMDP

LifeMD Inc. (LFMD) reported a strong Q4 and full-year 2025, with a 25% annual revenue increase and strategic advancements in AI and healthcare services. Despite a GAAP net loss for the quarter and anticipated Q1 2026 EBITDA loss due to high marketing investments in its GLP-1 weight loss business, the company is optimistic about future growth driven by new patient acquisitions, expanding services like Oral Wegovy, and AI integration. LifeMD is entering 2026 with a strong balance sheet, nearly 323,000 active subscribers, and no debt.